Alston, J. M., M. A. Andersen, J. S. James and P. G. Pardey (2010) Persistence Pays: U.S. Agricultural Productivity Growth and the Benefits from Public R&D Spending. New York: Springer.Google Scholar
Citeline (2013) Trialtrove, Available from https://citeline.com/products/trialtrove, Informa PLC.Google Scholar
Congressional Budget Office (2005) R&D and Productivity Growth. CBO Background Paper. Washington, DC: Congress of the United States.Google Scholar
Feinstein, A. R., D. M. Sosin and C. K. Wells (1985) “The Will Rogers Phenomenon: Stage Migration and New Diagnostic Techniques as a Source of Misleading Statistics for Survival in Cancer,” New England Journal of Medicine, 312(25):1604–1608.CrossrefGoogle Scholar
Ferrara, N. (2010). “From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials-an interview with Napoleone Ferrara by Domenico Ribatti.” The International Journal of Developmental Biology, 55(4–5):383–388.Google Scholar
Howlader, N., A. M. Noone, M. Krapcho, J. Garshell, N. Neyman, S. F. Altekruse, C. L. Kosary, R. J. M. Yu, Z. Tatalovich, H. Cho, A. Mariotto, D. R. Lewis, H. S. Chen, E. J. Feuer and K. A. Cronin. (eds) (2013) SEER Cancer Statistics Review (CSR), 1975–2010. Bethesda, MD: National Cancer Institute.Google Scholar
Hutchison, G. B. and S. Shapiro (1968) “Lead Time Gained by Diagnostic Screening for Breast Cancer,” Journal of National Cancer Institute, 41(3):665–681.Google Scholar
Kanavos, P., R. Sullivan, G. Lewison, W. Schurer, S. Eckhouse and Z. Vlachopioti (2010) “The Role of Funding and Policies on Innovation in Cancer Drug Development,” ecancer, 4(164).Google Scholar
Lakdawalla, D. N., E. C. Sun, A. B. Jena, C. M. Reyes, D. P. Goldman and T. J. Philipson (2010) “An economic Evaluation of the War on Cancer,” Journal of Health Economics, 29(3):333–346.CrossrefPubMedWeb of ScienceGoogle Scholar
Lichtenberg, F. R. (2009) “The Effect of New Cancer Drug Approvals on the Life Expectancy of American Cancer Patients, 1978–2004,” Economics of Innovation and New Technology, 18(5):407–428.CrossrefGoogle Scholar
Maruvka, Y. E., M. Tang and F. Michor (2014) “On the Validity of Using Increases in 5-Year Survival Rates to Measure Success in the Fight against Cancer,” PLoS ONE, 9(7):e83100.PubMedCrossrefWeb of ScienceGoogle Scholar
Mukherjee, S. (2011) The Emperor of all Maladies: A Biography of Cancer. New York: Simon and Schuster.Google Scholar
National Cancer Institute (1973–2010) The NCI Annual Fact Book. Retrieved November 1, 2013, from http://obf.cancer.gov/financial/factbook.htm.
National Cancer Institute (2013a) Interactive Budget Analysis Tool. Retrieved November 1, 2013, from http://budgettool.cancer.gov/.
National Cancer Institute (2014) “250 Years of Advances in Cancer.” Retrieved August 7, 2013, from http://www.cancer.gov/researchandfunding/progress/250-years-advances.
National Center for Health Statistics (2014) Health, United States, 2013: With Special Feature on Prescription Drugs, US Department of Health and Human Services, Centers for Disease Control and Prevention.Google Scholar
Pharmaceutical Research and Manufacturers of America (2013) Biopharmaceutical Research Industry Profile. Washington, DC: PhRMA.Google Scholar
Surveillance Epidemiology and End Results Program (1973–2011) Cancer Statistics, National Cancer Insititute.Google Scholar
United States Census Bureau (2013) 2015–2060 National Population Projections. Retrieved November 1, 2013, from http://www.census.gov/population/projections/data/national/2012.html.
United States Census Bureau (2014a) State & County QuickFacts. United States Census Bureau.Google Scholar
United States Census Bureau (2014b) Population. Washington, DC: United States Census Bureau.Google Scholar
Weinstein, M. C., J. E. Siegel, M. R. Gold, M. S. Kamlet and L. B. Russell (1996) “Recommendations of the Panel on Cost-effectiveness in Health and Medicine,” Journal of Medical Association 276(15):1253–1258.CrossrefGoogle Scholar
Online erschienen: 22.04.2015
Erschienen im Druck: 01.06.2016
Conflict of interest: Precision Health Economics is a consultancy to the health insurance and life science industries. AC holds the position of Chief Scientific Officer at Precision Health Economics. JPM and ACB are employees of Precision Health Economics. ZK is an employee of Celgene Corporation.
Research funding: None declared.
Author statement: This research was supported by Celgene Corporation under contract with Precision Health Economics. Precision Health Economics is a consultancy to the health insurance and life science industries. AC holds the position of Chief Scientific Officer at Precision Health Economics. JPM and ACB are employees of Precision Health Economics. ZK is an employee of Celgene Corporation.